AbbVie's MAVIRET now listed on the Newfoundland and Labrador formulary
A
bbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced that MAVIRET (glecaprevir/pibrentasvir tablets) is now listed on the Newfoundland and Labrador Formulary.
MAVIRET is a once-daily ribavirin-free treatment for adults and adolescent patients 12 to 18 years of age with chronic hepatitis C virus (HCV) infection across all major HCV genotypes (GT1-6).2 It is an 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment.
As a nurse practitioner, I see firsthand the devastating effects hepatitis C has in our communities and on those living with this disease. But we can change the narrative because we have all the right tools to eliminate this disease. We have the understanding, knowledge, resources and treatments like MAVIRET, to educate and treat everyone living with hepatitis C, says Kimberley A. Burt RN, BN, NP, Provincial Immunodeficiency Nurse Practitioner, Eastern Health, St. John's, Newfoundland.
MAVIRET is listed on the Newfoundland and Labrador Formulary for treatment-naive or treatment-experienced adult patients with chronic hepatitis C genotype 1,2,3,4,5 or 6 infection.3
Our vision is to work together to create a province without hepatitis C. To achieve this goal, we have to continue to raise awareness, educate, support people living with and/or affected by hepatitis C, as well as advocate for change, explains Gerard Yetman, Executive Director, AIDS Committee of Newfoundland and Labrador. We strongly believe that the newer treatments, such as MAVIRET, will have a positive impact and help us fulfill our mandate to eliminate hepatitis C from our province.
MAVIRET's efficacy and safety were evaluated in nine phase II-III clinical trials, in over 2300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis).
✔️ AbbVie's MAVIRET now listed on the Newfoundland and Labrador formulary
💕 Found this article helpful? Spread the word and support us!